Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Rao SPS, Barrett MP, Dranoff G, Faraday CJ, Gimpelewicz CR, Hailu A, Jones CL, Kelly JM, Lazdins-Helds JK, Mäser P, Mengel J, Mottram JC, Mowbray CE, Sacks DL, Scott P, Späth GF, Tarleton RL, Spector JM, Diagana TT.

ACS Infect Dis. 2018 Dec 13. doi: 10.1021/acsinfecdis.8b00298. [Epub ahead of print]

PMID:
30543391
2.

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A, Strub-Wourgaft N, Wasunna M, Wells S, Zijlstra EE, Arana B, Alvar J.

Clin Microbiol Rev. 2018 Aug 29;31(4). pii: e00048-18. doi: 10.1128/CMR.00048-18. Print 2018 Oct. Review.

PMID:
30158301
3.

Gene expression of AvBD6-10 in broiler chickens is independent of AvBD6, 9, and 10 peptide potency.

Mowbray CA, Niranji SS, Cadwell K, Bailey R, Watson KA, Hall J.

Vet Immunol Immunopathol. 2018 Aug;202:31-40. doi: 10.1016/j.vetimm.2018.06.007. Epub 2018 Jun 18.

PMID:
30078596
4.

High molecular weight hyaluronic acid: a two-pronged protectant against infection of the urogenital tract?

Mowbray CA, Shams S, Chung G, Stanton A, Aldridge P, Suchenko A, Pickard RS, Ali AS, Hall J.

Clin Transl Immunology. 2018 Jun 7;7(6):e1021. doi: 10.1002/cti2.1021. eCollection 2018.

5.

In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.

Van den Kerkhof M, Mabille D, Chatelain E, Mowbray CE, Braillard S, Hendrickx S, Maes L, Caljon G.

Int J Parasitol Drugs Drug Resist. 2018 Apr;8(1):81-86. doi: 10.1016/j.ijpddr.2018.01.006. Epub 2018 Jan 31.

6.

Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.

Thompson AM, Marshall AJ, Maes L, Yarlett N, Bacchi CJ, Gaukel E, Wring SA, Launay D, Braillard S, Chatelain E, Mowbray CE, Denny WA.

Bioorg Med Chem Lett. 2018 Jan 15;28(2):207-213. doi: 10.1016/j.bmcl.2017.10.067. Epub 2017 Oct 27.

7.

Targeting Deficiencies in the TLR5 Mediated Vaginal Response to Treat Female Recurrent Urinary Tract Infection.

Ali ASM, Mowbray C, Lanz M, Stanton A, Bowen S, Varley CL, Hilton P, Brown K, Robson W, Southgate J, Aldridge PD, Tyson-Capper A, Abraham S, Pickard RS, Hall J.

Sci Rep. 2017 Sep 8;7(1):11039. doi: 10.1038/s41598-017-10445-4.

8.

AvBD1 nucleotide polymorphisms, peptide antimicrobial activities and microbial colonisation of the broiler chicken gut.

Cadwell K, Niranji SS, Armstrong VL, Mowbray CA, Bailey R, Watson KA, Hall J.

BMC Genomics. 2017 Aug 18;18(1):637. doi: 10.1186/s12864-017-4034-6.

9.

Identifying a conceptual shift in child and adolescent-reported treatment decision making: "Having a say, as I need at this time".

Kelly KP, Mowbray C, Pyke-Grimm K, Hinds PS.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26262. Epub 2016 Nov 5.

PMID:
28221731
10.

Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.

Reeve BB, McFatrich M, Pinheiro LC, Freyer DR, Basch EM, Baker JN, Withycombe JS, Sung L, Mack JW, Waldron MK, Mowbray C, Palma D, Hinds PS.

J Pain Symptom Manage. 2017 Apr;53(4):759-766. doi: 10.1016/j.jpainsymman.2016.11.006. Epub 2017 Jan 3.

11.

Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.

Reeve BB, McFatrich M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26261. Epub 2016 Sep 21.

12.

Towards Profiles of Resistance Development and Toxicity for the Small Cationic Hexapeptide RWRWRW-NH2.

Wenzel M, Prochnow P, Mowbray C, Vuong C, Höxtermann S, Stepanek JJ, Albada HB, Hall J, Metzler-Nolte N, Bandow JE.

Front Cell Dev Biol. 2016 Aug 26;4:86. doi: 10.3389/fcell.2016.00086. eCollection 2016.

13.

Effects of rearing environment on the gut antimicrobial responses of two broiler chicken lines.

Butler VL, Mowbray CA, Cadwell K, Niranji SS, Bailey R, Watson KA, Ralph J, Hall J.

Vet Immunol Immunopathol. 2016 Oct 1;178:29-36. doi: 10.1016/j.vetimm.2016.06.004. Epub 2016 Jun 16.

PMID:
27496740
14.

Pilot Study of Massage to Improve Sleep and Fatigue in Hospitalized Adolescents With Cancer.

Jacobs S, Mowbray C, Cates LM, Baylor A, Gable C, Skora E, Estrada M, Cheng Y, Wang J, Lewin D, Hinds P.

Pediatr Blood Cancer. 2016 May;63(5):880-6. doi: 10.1002/pbc.25902. Epub 2016 Jan 12.

PMID:
26757318
15.

Nurse-Led Programs to Facilitate Enrollment to Children's Oncology Group Cancer Control Trials.

Haugen M, Kelly KP, Leonard M, Mills D, Sung L, Mowbray C, Landier W.

J Pediatr Oncol Nurs. 2016 Sep;33(5):387-91. doi: 10.1177/1043454215617458. Epub 2015 Nov 26. Review.

16.

Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity.

Mowbray CE, Braillard S, Speed W, Glossop PA, Whitlock GA, Gibson KR, Mills JE, Brown AD, Gardner JM, Cao Y, Hua W, Morgans GL, Feijens PB, Matheeussen A, Maes LJ.

J Med Chem. 2015 Dec 24;58(24):9615-24. doi: 10.1021/acs.jmedchem.5b01456. Epub 2015 Dec 4.

PMID:
26571076
17.

Hit and lead criteria in drug discovery for infectious diseases of the developing world.

Katsuno K, Burrows JN, Duncan K, Hooft van Huijsduijnen R, Kaneko T, Kita K, Mowbray CE, Schmatz D, Warner P, Slingsby BT.

Nat Rev Drug Discov. 2015 Nov;14(11):751-8. doi: 10.1038/nrd4683. Epub 2015 Oct 5. Review.

PMID:
26435527
18.

Concept-elicitation phase for the development of the pediatric patient-reported outcome version of the Common Terminology Criteria for Adverse Events.

Weaver MS, Reeve BB, Baker JN, Martens CE, McFatrich M, Mowbray C, Palma D, Sung L, Tomlinson D, Withycombe J, Hinds P.

Cancer. 2016 Jan 1;122(1):141-8. doi: 10.1002/cncr.29702. Epub 2015 Sep 30.

19.

Treatment options for second-stage gambiense human African trypanosomiasis.

Eperon G, Balasegaram M, Potet J, Mowbray C, Valverde O, Chappuis F.

Expert Rev Anti Infect Ther. 2014 Nov;12(11):1407-17. doi: 10.1586/14787210.2014.959496. Epub 2014 Sep 10. Review.

20.

Severe lactic acidosis and multiorgan failure due to thiamine deficiency during total parenteral nutrition.

Ramsi M, Mowbray C, Hartman G, Pageler N.

BMJ Case Rep. 2014 Jun 3;2014. pii: bcr2014205264. doi: 10.1136/bcr-2014-205264.

21.

The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians.

Reeve BB, Withycombe JS, Baker JN, Hooke MC, Lyons JC, Mowbray C, Wang J, Freyer DR, Joffe S, Sung L, Tomlinson D, Gold SH, Hinds PS.

Pediatr Blood Cancer. 2013 Jul;60(7):1231-6. doi: 10.1002/pbc.24463. Epub 2013 Jan 17.

PMID:
23335328
22.

Synthesis of novel histamine H4 receptor antagonists.

Lane CA, Hay D, Mowbray CE, Paradowski M, Selby MD, Swain NA, Williams DH.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1156-9. doi: 10.1016/j.bmcl.2011.11.098. Epub 2011 Dec 1.

PMID:
22189138
23.

Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).

Masood MA, Selby MD, Bell AS, Mansfield AC, Gardner M, Smith GF, Lane C, Kenyon-Edwards H, Osborne R, Jones RM, Liu WL, Brown CD, Clarke N, Perrucio F, Mowbray CE.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6591-5. doi: 10.1016/j.bmcl.2011.07.114. Epub 2011 Aug 27.

PMID:
21955944
24.

Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.

Mowbray CE, Bell AS, Clarke NP, Collins M, Jones RM, Lane CA, Liu WL, Newman SD, Paradowski M, Schenck EJ, Selby MD, Swain NA, Williams DH.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. doi: 10.1016/j.bmcl.2011.07.125. Epub 2011 Aug 9.

PMID:
21920751
25.

Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers.

Jones LH, Allan G, Corbau R, Middleton DS, Mowbray CE, Newman SD, Phillips C, Webster R, Westby M.

Chem Biol Drug Des. 2011 May;77(5):393-7. doi: 10.1111/j.1747-0285.2011.01113.x. Epub 2011 Mar 29.

PMID:
21352504
26.

Mitochondrial DNA does not contribute to the heritability of non-alcoholic fatty liver disease.

de Alwis N, Aithal G, Bugianesi E, Leathart J, Hudson G, Pyle A, Mowbray C, Henderson E, Burt AD, Chinnery PF, Day CP.

Mitochondrion. 2011 Jan;11(1):234-5. doi: 10.1016/j.mito.2010.09.009. Epub 2010 Oct 1. No abstract available.

PMID:
20888438
27.

Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.

Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M.

Antimicrob Agents Chemother. 2010 Oct;54(10):4451-63. doi: 10.1128/AAC.01455-09. Epub 2010 Jul 26.

28.

Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.

Mowbray CE, Burt C, Corbau R, Gayton S, Hawes M, Perros M, Tran I, Price DA, Quinton FJ, Selby MD, Stupple PA, Webster R, Wood A.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5857-60. doi: 10.1016/j.bmcl.2009.08.080. Epub 2009 Aug 27.

PMID:
19748778
29.

Pyrazole NNRTIs 3: optimisation of physicochemical properties.

Mowbray CE, Corbau R, Hawes M, Jones LH, Mills JE, Perros M, Selby MD, Stupple PA, Webster R, Wood A.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5603-6. doi: 10.1016/j.bmcl.2009.08.043. Epub 2009 Aug 14.

PMID:
19717303
30.

Pyrazole NNRTIs 1: design and initial optimisation of a novel template.

Mowbray CE, Burt C, Corbau R, Perros M, Tran I, Stupple PA, Webster R, Wood A.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5599-602. doi: 10.1016/j.bmcl.2009.08.039. Epub 2009 Aug 13.

PMID:
19709880
31.

Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction.

Williams DH, Adam F, Fenwick DR, Fok-Seang J, Gardner I, Hay D, Jaiessh R, Middleton DS, Mowbray CE, Parkinson T, Perros M, Pickford C, Platts M, Randall A, Siddle D, Stephenson PT, Tran TD, Vuong H.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5246-9. doi: 10.1016/j.bmcl.2009.06.080. Epub 2009 Jun 25.

PMID:
19620004
32.

A late role for bmp2b in the morphogenesis of semicircular canal ducts in the zebrafish inner ear.

Hammond KL, Loynes HE, Mowbray C, Runke G, Hammerschmidt M, Mullins MC, Hildreth V, Chaudhry B, Whitfield TT.

PLoS One. 2009;4(2):e4368. doi: 10.1371/journal.pone.0004368. Epub 2009 Feb 3.

33.

Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.

Jones LH, Allan G, Barba O, Burt C, Corbau R, Dupont T, Knöchel T, Irving S, Middleton DS, Mowbray CE, Perros M, Ringrose H, Swain NA, Webster R, Westby M, Phillips C.

J Med Chem. 2009 Feb 26;52(4):1219-23. doi: 10.1021/jm801322h.

PMID:
19175319
34.

A zebrafish model for Waardenburg syndrome type IV reveals diverse roles for Sox10 in the otic vesicle.

Dutton K, Abbas L, Spencer J, Brannon C, Mowbray C, Nikaido M, Kelsh RN, Whitfield TT.

Dis Model Mech. 2009 Jan-Feb;2(1-2):68-83. doi: 10.1242/dmm.001164. Epub 2008 Dec 22.

35.

Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.

Jones LH, Allan G, Corbau R, Hay D, Middleton DS, Mowbray CE, Newman SD, Perros M, Randall A, Vuong H, Webster R, Westby M, Williams D.

ChemMedChem. 2008 Nov;3(11):1756-62. doi: 10.1002/cmdc.200800183.

PMID:
18855969
36.

Small, non-peptide C5a receptor antagonists: part 1.

Blagg J, Mowbray C, Pryde DC, Salmon G, Schmid E, Fairman D, Beaumont K.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5601-4. doi: 10.1016/j.bmcl.2008.08.106. Epub 2008 Aug 31.

PMID:
18809326
37.

Small, non-peptide C5a receptor antagonists: part 2.

Blagg J, Mowbray C, Pryde D, Salmon G, Fairman D, Schmid E, Beaumont K.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5605-8. doi: 10.1016/j.bmcl.2008.08.101. Epub 2008 Aug 31.

PMID:
18804369
38.

Characteristics of users of consumer-run drop-in centers versus clubhouses.

Mowbray CT, Woodward AT, Holter MC, MacFarlane P, Bybee D.

J Behav Health Serv Res. 2009 Jul;36(3):361-71. doi: 10.1007/s11414-008-9112-8.

PMID:
18563574
39.

Using planned adaptation to implement evidence-based programs with new populations.

Lee SJ, Altschul I, Mowbray CT.

Am J Community Psychol. 2008 Jun;41(3-4):290-303. doi: 10.1007/s10464-008-9160-5.

PMID:
18307029
40.

Mothers with serious mental illness: when symptoms decline does parenting improve?

Kahng SK, Oyserman D, Bybee D, Mowbray C.

J Fam Psychol. 2008 Feb;22(1):162-6. doi: 10.1037/0893-3200.22.1.162.

PMID:
18266543
41.

An investigation of mitochondrial haplogroups in autism.

Kent L, Gallagher L, Elliott HR, Mowbray C, Chinnery PF.

Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):987-9.

PMID:
18161860
42.

The influence of gender, patient volume and time on clinical diagnostic decision making in psychiatric emergency services.

Muroff JR, Jackson JS, Mowbray CT, Himle JA.

Gen Hosp Psychiatry. 2007 Nov-Dec;29(6):481-8.

PMID:
18022040
43.

Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?

Hudson G, Mowbray C, Elson JL, Jacob A, Boggild M, Torroni A, Chinnery PF.

Brain. 2008 Apr;131(Pt 4):e93. Epub 2007 Oct 29. Review. No abstract available.

PMID:
17967805
44.

Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background.

Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A, Pyle A, Elson J, Howell N, La Morgia C, Valentino ML, Huoponen K, Savontaus ML, Nikoskelainen E, Sadun AA, Salomao SR, Belfort R Jr, Griffiths P, Yu-Wai-Man P, de Coo RF, Horvath R, Zeviani M, Smeets HJ, Torroni A, Chinnery PF.

Am J Hum Genet. 2007 Aug;81(2):228-33. Epub 2007 Jun 4.

45.

Mitochondrial DNA haplogroups and type 2 diabetes: a study of 897 cases and 1010 controls.

Chinnery PF, Mowbray C, Patel SK, Elson JL, Sampson M, Hitman GA, McCarthy MI, Hattersley AT, Walker M.

J Med Genet. 2007 Jun;44(6):e80.

46.

Relevance of spirituality for people with mental illness attending consumer-centered services.

Bellamy CD, Jarrett NC, Mowbray O, MacFarlane P, Mowbray CT, Holter MC.

Psychiatr Rehabil J. 2007 Spring;30(4):287-94.

PMID:
17458452
47.

Mitochondrial DNA haplogroups and amyotrophic lateral sclerosis.

Chinnery PF, Mowbray C, Elliot H, Elson JL, Nixon H, Hartley J, Shaw PJ.

Neurogenetics. 2007 Jan;8(1):65-7. Epub 2006 Nov 3. No abstract available.

PMID:
17082949
48.

The clubhouse as an empowering setting.

Mowbray CT, Lewandowski L, Holter M, Bybee D.

Health Soc Work. 2006 Aug;31(3):167-79.

PMID:
16955655
49.

Psychosocial outcomes for adult children of parents with severe mental illnesses: demographic and clinical history predictors.

Mowbray CT, Bybee D, Oyserman D, MacFarlane P, Bowersox N.

Health Soc Work. 2006 May;31(2):99-108.

PMID:
16776027
50.

Campus mental health services: recommendations for change.

Mowbray CT, Megivern D, Mandiberg JM, Strauss S, Stein CH, Collins K, Kopels S, Curlin C, Lett R.

Am J Orthopsychiatry. 2006 Apr;76(2):226-37.

PMID:
16719642

Supplemental Content

Loading ...
Support Center